Hospital
Grossmont Hospital Corporation
Grossmont Hospital Corporation was paid $226.70M by Medicaid between Jan 2018 and Dec 2024, across 449 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoGROSSMONT HOSPITAL CORPORATION
LA MESA, CA 91942
LA MESA, CA 91942
33aNPI1528041811assigned 11/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$226.70M
24GClaims2,443,214
24DCodes billed449
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#2 of 410
Median peer was paid$6.90M
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 380,295 | $32.72M | |
| 2019 | 401,379 | $31.84M | |
| 2020 | 318,264 | $26.35M | |
| 2021 | 386,116 | $33.37M | |
| 2022 | 402,299 | $39.35M | |
| 2023 | 348,267 | $38.10M | |
| 2024incomplete | 206,594 | $24.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 77,724 | 71,179 | $34.21M |
| 0450 | Emergency room services | 14% | 110,845 | 100,176 | $31.89M |
| 99499 | 6.1% | 53,161 | 42,400 | $13.94M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 18,424 | 17,967 | $12.41M |
| 99199 | Unlisted special service, procedure or report | 3.4% | 11,446 | 8,614 | $7.69M |
| 80053 | Comprehensive metabolic panel | 3.0% | 171,205 | 153,027 | $6.89M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 22,906 | 22,029 | $5.70M |
| 0762 | 2.5% | 11,662 | 5,867 | $5.60M | |
| 0360 | 2.2% | 5,991 | 3,167 | $4.99M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 74,849 | 66,487 | $4.27M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.8% | 14,500 | 13,033 | $4.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 11,282 | 10,186 | $4.09M |
437 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 187,789 | $3.38M |
| 0121 | 1.5% | 446 | $3.33M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 6,455 | $2.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 35,135 | $2.60M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 33,131 | $2.55M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.0% | 2,952 | $2.28M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,550 | $2.25M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 39,733 | $2.13M |
| 0206 | <1% | 215 | $1.87M | |
| 0160 | <1% | 2,745 | $1.82M | |
| 95811 | <1% | 2,662 | $1.81M | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,684 | $1.64M |
| 84484 | <1% | 54,449 | $1.50M | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12,185 | $1.40M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 25,156 | $1.39M |
| 59025 | Fetal non-stress test | <1% | 9,583 | $1.36M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 34,380 | $1.35M |
| 71045 | Radiologic examination, chest; single view | <1% | 32,149 | $1.33M |
| 76801 | <1% | 9,111 | $1.33M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,847 | $1.30M |
| 0519 | <1% | 16,636 | $1.17M | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,064 | $1.12M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,837 | $1.10M |
| Z7502 | <1% | 30,161 | $1.10M | |
| 97139 | <1% | 34,620 | $1.09M | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,675 | $1.07M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 27,948 | $1.04M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,311 | $1.03M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,981 | $960K |
| 81001 | <1% | 68,639 | $945K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,648 | $940K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,756 | $940K |
| 83690 | <1% | 43,398 | $900K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,444 | $882K |
| 82962 | <1% | 46,636 | $799K | |
| 70486 | <1% | 2,389 | $799K | |
| 93971 | <1% | 4,796 | $778K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,906 | $744K |
| 0300 | <1% | 818 | $717K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,398 | $683K |
| 0710 | <1% | 3,578 | $671K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,331 | $669K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,602 | $627K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,418 | $619K |
| 76830 | Ultrasound, transvaginal | <1% | 4,857 | $617K |
| 93970 | <1% | 2,928 | $604K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,638 | $560K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23,365 | $557K |
| 82077 | <1% | 15,232 | $535K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 20,547 | $514K |
| 71250 | <1% | 2,391 | $509K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,883 | $508K |
| 87040 | <1% | 7,170 | $505K | |
| 72100 | <1% | 8,538 | $492K | |
| 99219 | <1% | 766 | $484K | |
| 0721 | <1% | 7,672 | $475K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,914 | $466K |
| 76770 | <1% | 5,578 | $454K | |
| 73562 | <1% | 8,883 | $453K | |
| 73630 | <1% | 7,752 | $443K | |
| 97799 | <1% | 13,599 | $434K | |
| 73030 | <1% | 6,953 | $429K | |
| 0250 | <1% | 6,075 | $404K | |
| 70491 | <1% | 1,130 | $403K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 23,312 | $397K |
| 84703 | <1% | 28,344 | $393K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,171 | $373K |
| G0378 | Hospital observation service, per hour | <1% | 2,218 | $366K |
| 84702 | <1% | 9,423 | $363K | |
| 74178 | <1% | 649 | $360K | |
| 73610 | <1% | 5,694 | $357K | |
| 73130 | <1% | 5,643 | $331K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,434 | $327K |
| 83735 | <1% | 20,546 | $323K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 926 | $316K |
| 83880 | <1% | 13,574 | $315K | |
| 85610 | <1% | 22,549 | $302K | |
| 76813 | <1% | 3,539 | $292K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,399 | $289K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,220 | $289K |
| Z9725 | <1% | 6,432 | $277K | |
| 72040 | <1% | 4,383 | $275K | |
| 70498 | <1% | 594 | $274K | |
| 93976 | <1% | 1,588 | $272K | |
| 0760 | <1% | 4,742 | $256K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,331 | $256K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 2,571 | $251K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,824 | $244K |
| 97161 | <1% | 4,795 | $243K | |
| 80143 | <1% | 5,934 | $225K | |
| 70496 | <1% | 532 | $218K | |
| 73700 | <1% | 1,100 | $217K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,268 | $217K |
| 80179 | <1% | 5,843 | $213K | |
| 73110 | <1% | 3,608 | $210K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,530 | $203K |
| 76870 | <1% | 1,454 | $201K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,395 | $198K |
| J3490 | Unclassified drugs | <1% | 5,372 | $193K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 711 | $190K |
| 0410 | <1% | 251 | $190K | |
| 76536 | <1% | 1,902 | $189K | |
| 85730 | <1% | 17,048 | $187K | |
| 77336 | <1% | 2,040 | $183K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,682 | $181K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,254 | $179K |
| 87081 | <1% | 8,501 | $179K | |
| 93017 | <1% | 1,182 | $177K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 702 | $176K |
| 85379 | <1% | 7,066 | $171K | |
| 0270 | <1% | 1,489 | $159K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,491 | $157K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,241 | $155K |
| 77386 | <1% | 151 | $153K | |
| 82550 | <1% | 8,821 | $147K | |
| 73080 | <1% | 2,371 | $141K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,461 | $138K |
| 73502 | <1% | 3,613 | $137K | |
| 83605 | <1% | 9,875 | $136K | |
| 86900 | <1% | 6,077 | $134K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 727 | $133K |
| 71101 | <1% | 1,822 | $130K | |
| 72072 | <1% | 1,976 | $122K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 949 | $116K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,668 | $116K |
| 77412 | <1% | 1,059 | $115K | |
| 0352 | <1% | 163 | $110K | |
| 70480 | <1% | 367 | $108K | |
| 86901 | <1% | 6,067 | $104K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 436 | $104K |
| 81003 | <1% | 11,737 | $103K | |
| 76820 | <1% | 2,075 | $100K | |
| Z7500 | <1% | 2,974 | $100K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 910 | $98K |
| 73590 | <1% | 2,119 | $98K | |
| 0258 | <1% | 6,720 | $96K | |
| 93880 | <1% | 1,017 | $95K | |
| 0489 | <1% | 151 | $94K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 3,005 | $93K |
| 12001 | <1% | 982 | $91K | |
| 74018 | <1% | 2,760 | $89K | |
| 77334 | <1% | 228 | $87K | |
| 59425 | <1% | 1,583 | $86K | |
| 70544 | <1% | 411 | $85K | |
| 97162 | <1% | 3,932 | $84K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,184 | $83K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 247 | $82K |
| 0761 | <1% | 2,141 | $79K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,796 | $78K |
| 0351 | <1% | 174 | $77K | |
| 87510 | <1% | 5,294 | $77K | |
| 87480 | <1% | 5,328 | $76K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 9,694 | $76K |
| 87660 | <1% | 5,328 | $75K | |
| 97116 | <1% | 5,659 | $74K | |
| 71271 | <1% | 389 | $74K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,672 | $69K |
| 90715 | <1% | 3,587 | $68K | |
| 80061 | Lipid panel | <1% | 9,119 | $62K |
| 94799 | <1% | 2,379 | $62K | |
| 97014 | <1% | 5,554 | $62K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28,823 | $62K |
| 0730 | <1% | 578 | $59K | |
| 96376 | <1% | 2,152 | $59K | |
| 73140 | <1% | 1,427 | $59K | |
| 0324 | <1% | 619 | $59K | |
| 72110 | <1% | 811 | $59K | |
| 87186 | <1% | 5,596 | $55K | |
| 73090 | <1% | 1,104 | $53K | |
| 0272 | <1% | 407 | $51K | |
| 84100 | <1% | 4,481 | $50K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,234 | $50K |
| 93325 | <1% | 511 | $50K | |
| 0402 | <1% | 204 | $49K | |
| 93458 | <1% | 42 | $49K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,040 | $48K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,916 | $47K |
| 87631 | <1% | 1,435 | $47K | |
| 29125 | <1% | 837 | $47K | |
| 86850 | <1% | 2,347 | $47K | |
| 10060 | <1% | 477 | $44K | |
| 87077 | <1% | 6,304 | $43K | |
| 87641 | <1% | 2,390 | $41K | |
| 73560 | <1% | 1,244 | $41K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,161 | $41K |
| 86140 | <1% | 4,233 | $41K | |
| 85027 | <1% | 4,405 | $40K | |
| 0420 | <1% | 358 | $39K | |
| 84439 | <1% | 5,215 | $38K | |
| 77300 | <1% | 197 | $37K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,224 | $35K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 317 | $34K |
| 74022 | <1% | 534 | $34K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,351 | $34K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,666 | $33K |
| C1776 | Joint device (implantable) | <1% | 29 | $32K |
| 74221 | <1% | 336 | $32K | |
| 75574 | <1% | 85 | $31K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 132 | $31K |
| 80164 | <1% | 2,218 | $31K | |
| 84145 | <1% | 1,922 | $31K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,906 | $30K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 268 | $28K |
| 80047 | <1% | 1,236 | $27K | |
| 10005 | <1% | 110 | $27K | |
| 72141 | <1% | 77 | $26K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,934 | $26K |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 1,998 | $26K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,737 | $25K |
| 87070 | <1% | 2,348 | $25K | |
| 72050 | <1% | 342 | $24K | |
| 19083 | <1% | 34 | $23K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 111 | $23K |
| 95808 | <1% | 59 | $22K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,936 | $22K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,477 | $21K |
| 76825 | <1% | 115 | $21K | |
| 72170 | <1% | 383 | $21K | |
| 62323 | <1% | 196 | $20K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 115 | $19K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,818 | $19K |
| 97166 | <1% | 812 | $18K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 449 | $18K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,494 | $18K |
| 74183 | <1% | 65 | $18K | |
| 73552 | <1% | 496 | $18K | |
| 83615 | <1% | 1,566 | $18K | |
| 99401 | <1% | 1,743 | $17K | |
| 0320 | <1% | 132 | $17K | |
| 82009 | <1% | 2,546 | $17K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 477 | $17K |
| 74174 | <1% | 39 | $17K | |
| 84550 | <1% | 2,849 | $17K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,274 | $16K |
| 87807 | <1% | 439 | $16K | |
| 74220 | <1% | 222 | $16K | |
| 97803 | <1% | 329 | $16K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 29 | $16K |
| 73620 | <1% | 386 | $15K | |
| 85652 | <1% | 3,196 | $15K | |
| 73060 | <1% | 413 | $14K | |
| 12002 | <1% | 161 | $14K | |
| 70487 | <1% | 31 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,201 | $14K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,499 | $14K |
| 97035 | <1% | 1,121 | $14K | |
| 82728 | <1% | 2,793 | $14K | |
| 85384 | <1% | 580 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,264 | $13K |
| 97802 | <1% | 1,088 | $12K | |
| 82248 | <1% | 2,811 | $12K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 657 | $12K |
| 82570 | <1% | 3,374 | $12K | |
| 94660 | <1% | 80 | $12K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,816 | $11K |
| 82553 | <1% | 396 | $11K | |
| 97165 | <1% | 238 | $11K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 434 | $11K |
| 80178 | <1% | 661 | $11K | |
| 86923 | <1% | 175 | $11K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,192 | $10K |
| 81025 | <1% | 2,825 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,589 | $10K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,152 | $10K |
| 97163 | <1% | 193 | $10K | |
| 87427 | <1% | 353 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,604 | $10K |
| 86308 | <1% | 474 | $10K | |
| 76827 | <1% | 114 | $10K | |
| 82140 | <1% | 955 | $9K | |
| 64483 | <1% | 30 | $9K | |
| 82805 | <1% | 235 | $9K | |
| 73660 | <1% | 203 | $9K | |
| 88304 | <1% | 317 | $9K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,609 | $9K |
| 12011 | <1% | 141 | $9K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 120 | $8K |
| 87045 | <1% | 454 | $8K | |
| 97172 | <1% | 133 | $8K | |
| 83540 | <1% | 3,016 | $8K | |
| 87205 | <1% | 2,088 | $8K | |
| 30520 | <1% | 25 | $8K | |
| 85014 | <1% | 1,275 | $8K | |
| 97010 | <1% | 796 | $8K | |
| 0370 | <1% | 550 | $8K | |
| 71020 | <1% | 234 | $7K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 38 | $7K |
| 83550 | <1% | 2,690 | $7K | |
| 0002A | <1% | 193 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,022 | $7K |
| 82731 | <1% | 68 | $7K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 28 | $7K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,793 | $6K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,301 | $6K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 848 | $6K |
| 76882 | <1% | 126 | $6K | |
| 87046 | <1% | 455 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,244 | $5K |
| 93923 | <1% | 96 | $5K | |
| A6211 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | <1% | 127 | $5K |
| 76942 | <1% | 69 | $5K | |
| 0001A | <1% | 150 | $5K | |
| 73564 | <1% | 67 | $5K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 611 | $5K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 29 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 605 | $5K |
| 88342 | <1% | 233 | $5K | |
| 30140 | <1% | 15 | $5K | |
| 88307 | <1% | 70 | $5K | |
| 0301 | <1% | 190 | $5K | |
| 82607 | <1% | 1,664 | $5K | |
| 87340 | <1% | 707 | $4K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 20 | $4K |
| 85670 | <1% | 177 | $4K | |
| 87653 | <1% | 271 | $4K | |
| 96367 | <1% | 120 | $4K | |
| C1769 | Guide wire | <1% | 186 | $4K |
| 0004A | <1% | 121 | $4K | |
| 87449 | <1% | 512 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 255 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 255 | $4K |
| 74230 | <1% | 63 | $4K | |
| 96156 | <1% | 360 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,101 | $3K |
| 97012 | <1% | 322 | $3K | |
| 92611 | <1% | 85 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 599 | $3K |
| 84153 | <1% | 1,106 | $3K | |
| 86780 | <1% | 723 | $3K | |
| 73120 | <1% | 65 | $3K | |
| 43235 | <1% | 24 | $3K | |
| 95816 | <1% | 20 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,814 | $3K |
| 29130 | <1% | 52 | $3K | |
| 73221 | <1% | 16 | $2K | |
| 92610 | <1% | 74 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 796 | $2K |
| Z7610 | <1% | 508 | $2K | |
| 0430 | <1% | 68 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 603 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 45 | $2K |
| A4565 | Slings | <1% | 201 | $2K |
| 92523 | <1% | 38 | $2K | |
| 86803 | <1% | 306 | $2K | |
| 71010 | <1% | 79 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 29 | $2K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 500 | $2K |
| 86480 | <1% | 241 | $2K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 200 | $2K |
| 73070 | <1% | 41 | $2K | |
| 27447 | <1% | 13 | $2K | |
| 72220 | <1% | 25 | $2K | |
| 82746 | <1% | 662 | $2K | |
| 29515 | <1% | 28 | $2K | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 30 | $1K |
| 99221 | <1% | 97 | $1K | |
| 86762 | <1% | 209 | $1K | |
| 83970 | <1% | 438 | $1K | |
| 93922 | <1% | 27 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $1K |
| 87899 | <1% | 51 | $1K | |
| 87147 | <1% | 202 | $1K | |
| 99234 | <1% | 66 | $1K | |
| 76642 | <1% | 15 | $1K | |
| 76857 | <1% | 12 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,013 | $1K |
| 82150 | <1% | 74 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,196 | $1K |
| 72070 | <1% | 13 | $1K | |
| 97597 | <1% | 25 | $989.08 | |
| 0274 | <1% | 18 | $975.51 | |
| 80185 | <1% | 75 | $955.80 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 29 | $951.67 |
| 95992 | <1% | 72 | $942.24 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 162 | $921.17 |
| 87075 | <1% | 178 | $919.32 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 87 | $906.50 |
| 82951 | <1% | 42 | $873.35 | |
| 0440 | <1% | 15 | $852.25 | |
| 82043 | <1% | 1,825 | $843.52 | |
| 80074 | <1% | 28 | $827.16 | |
| 88173 | <1% | 67 | $772.87 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 52 | $763.21 |
| 87324 | <1% | 105 | $757.78 | |
| 70360 | <1% | 13 | $702.16 | |
| 86038 | <1% | 288 | $658.16 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 104 | $634.84 |
| 90732 | <1% | 26 | $623.56 | |
| 85347 | <1% | 65 | $619.29 | |
| 87634 | <1% | 13 | $603.99 | |
| 87640 | <1% | 83 | $583.56 | |
| 86141 | <1% | 89 | $548.12 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $495.52 |
| 74019 | <1% | 12 | $452.14 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 98 | $450.88 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 218 | $444.41 |
| 82803 | <1% | 15 | $442.08 | |
| 97022 | <1% | 21 | $438.12 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 64 | $430.10 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 98 | $424.13 |
| 80076 | <1% | 70 | $366.91 | |
| 82378 | <1% | 166 | $339.40 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 21 | $335.49 |
| S9999 | Sales tax | <1% | 21 | $304.50 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 17 | $297.60 |
| 88300 | <1% | 26 | $270.40 | |
| 90686 | <1% | 44 | $253.89 | |
| 85018 | <1% | 172 | $243.64 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 14 | $241.22 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 151 | $221.92 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 20 | $220.18 |
| 90674 | <1% | 46 | $220.16 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 24 | $184.75 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 89 | $167.54 |
| 86787 | <1% | 49 | $157.11 | |
| 86039 | <1% | 16 | $144.49 | |
| 96150 | <1% | 17 | $133.84 | |
| 90662 | <1% | 37 | $124.95 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 44 | $124.36 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 40 | $118.96 |
| 82565 | <1% | 40 | $118.38 | |
| 86200 | <1% | 59 | $107.18 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 27 | $89.80 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 110 | $86.09 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 326 | $71.80 |
| 80069 | <1% | 47 | $70.94 | |
| 81015 | <1% | 13 | $61.75 | |
| 86430 | <1% | 41 | $50.18 | |
| 84480 | <1% | 13 | $45.02 | |
| 83021 | <1% | 12 | $18.44 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13 | $9.98 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 25 | $1.33 |
| 91300 | <1% | 283 | $0.02 | |
| 91307 | <1% | 38 | $0.01 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 174 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 26 | $0.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 211 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEVANS, SCOTT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Grossmont Hospital Corporation | San Diego, CA | $3.66M |
| Massachusetts Eye Research and Surgery Institution, PC | Waltham, MA | $78K |
| Grossmont Hospital Corporation | La Mesa, CA | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.